Federated Hermes, Inc. Biogen Inc. Transaction History

Federated Hermes, Inc.

$41.2 Billion
Q2 2024

A detailed history of Federated Hermes, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 102,942 shares of BIIB stock, worth $17.9 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

102,942

Previous 102,724 0.21%

Holding current value

$17.9 Million

Previous $22.2 Million 7.74%

% of portfolio

0.06%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$190.52 - $236.72 $41,533 - $51,604	218 Added 0.21%	102,942 $23.9 Million
Q1 2024 May 14, 2024	BUY	$212.02 - $267.71 $546,163 - $689,620	2,576 Added 2.57%	102,724 $22.2 Million
Q4 2023 Jan 31, 2024	SELL	$222.59 - $267.94 $961,588 - $1.16 Million	-4,320 Reduced 4.14%	100,148 $25.9 Million
Q3 2023 Nov 13, 2023	BUY	$253.3 - $285.89 $11.2 Million - $12.7 Million	44,328 Added 73.71%	104,468 $26.8 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $751,707 - $868,621	-2,731 Reduced 4.34%	60,140 $17.1 Million
Q1 2023 May 08, 2023	BUY	$256.56 - $292.34 $64,140 - $73,085	250 Added 0.4%	62,871 $17.5 Million
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $18.2 Million - $22.1 Million	-72,028 Reduced 53.49%	62,621 $17.3 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $34.5 Million - $47.6 Million	-177,323 Reduced 56.84%	134,649 $36 Million
Q2 2022 Aug 15, 2022	BUY	$187.54 - $223.02 $17.3 Million - $20.5 Million	91,985 Added 41.81%	311,972 $63.6 Million
Q1 2022 May 13, 2022	BUY	$193.77 - $244.14 $29.2 Million - $36.8 Million	150,537 Added 216.76%	219,987 $46.3 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $14.3 Million - $18.4 Million	64,015 Added 1177.83%	69,450 $16.7 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $43,014 - $56,095	-152 Reduced 2.72%	5,435 $1.54 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $464,128 - $743,160	-1,792 Reduced 24.29%	5,587 $1.94 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $14.9 Million - $17.4 Million	-61,203 Reduced 89.24%	7,379 $2.06 Million
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $10.2 Million - $15.3 Million	-43,012 Reduced 38.54%	68,582 $16.8 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $24.3 Million - $28 Million	-91,748 Reduced 45.12%	111,594 $31.7 Million
Q2 2020 Aug 13, 2020	BUY	$258.66 - $342.55 $15.2 Million - $20.1 Million	58,606 Added 40.49%	203,342 $54.4 Million
Q1 2020 May 13, 2020	SELL	$268.85 - $341.04 $3.8 Million - $4.82 Million	-14,130 Reduced 8.89%	144,736 $45.8 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $35.6 Million - $49.2 Million	-161,853 Reduced 50.47%	158,866 $47.1 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $11.9 Million - $13.4 Million	54,821 Added 20.62%	320,719 $74.7 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $11.3 Million - $12.4 Million	51,424 Added 23.98%	265,898 $62.2 Million
Q1 2019 May 10, 2019	SELL	$216.71 - $338.96 $6.91 Million - $10.8 Million	-31,893 Reduced 12.95%	214,474 $50.7 Million
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $5.92 Million - $7.5 Million	21,274 Added 9.45%	246,367 $74.1 Million
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $65 Million - $85 Million	221,374 Added 5952.51%	225,093 $79.5 Million
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $7,725 - $9,207	-30 Reduced 0.8%	3,719 $1.08 Million
Q1 2018 May 09, 2018	SELL	$260.13 - $367.91 $15,087 - $21,338	-58 Reduced 1.52%	3,749 $1.03 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $31,379 - $35,147	102 Added 2.75%	3,807 $0
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $1.04 Million - $1.22 Million	3,705	3,705 $1.16 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Biogen Inc. Transaction History